Global Short Bowel Syndrome Market

Short Bowel Syndrome Market is Expected to Grow at Exponential Pace During Forecast Period of 2022-2027 

Short Bowel Syndrome (SBS) is a group of problems related to poor absorption of nutrients. The main cause of SBS is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, and birth defects. Some people are born with an abnormally short small intestine, significant damage, and poor motility, which can cause short bowel syndrome. Presently, there is no cure for SBS and the treatment is targeted toward symptoms. In a few cases, SBS can be life-threatening but usually, the disease can be managed through effective medication. 

Market Size & Growth Rate: 

The SBS market was valued at USD 1.24 billion in 2021 and is expected to reach USD 4.42 billion by 2027, and is projected to expand at a CAGR of 15.9% during the forecast period 2022-2027. Due to significant research & development, innovative medicines, extensive research, disease prevalence, and favorable reimbursement scenario are anticipated to propel the global short bowel syndrome market. 

Market Dynamics: 

The high cost of parenteral nutrition, favorable reimbursement policies, and increased awareness programs enhanced by various associations like the association of gastrointestinal motility, oley foundations, aspen (clinical nutrition), and the SBS therapeutic project along with increasing government healthcare investments are to project the market growth over the forecast period. 

According to Crohn’s & Coiltis Foundation, SBS affects about three out of every million people each year and approximately 10,000–20,000 people in the United States have short bowel syndrome. Moreover, doctors may remove the small intestine as part of various treatments for Crohn's disease, cancer, and damage from cancer treatment like radiation therapy.                                                                              

In addition, according to WHO-2022, colon & rectum cancers are one of the leading causes of death worldwide, accounting for nearly 1.93 million cases and 916 000 deaths around the globe, these numbers are expected to stimulate the demand for short bowel syndrome medicines through 2027. 

Market Drivers: 

• Oral rehydration products and prescription medicines enhance the certain revenue growth 

• Nutritional support, medications, and surgery are the most preferred treatment options for SBS. To prevent dehydration in children are also recommended special drinks containing salts and minerals like CeraLyte Pedialyte, and Infalyte, are available at medical stores and grocery stores. 

• Manufacturers in the short bowel syndrome market are establishing stable income sources through prescription medicines such as antibiotics, H2 blockers, proton pump inhibitors, and the like to improve patient outcomes 

• Glucagon-like Peptide-2 (GLP-2) to dominate the global market 

• The GLP-2 is anticipated to be one of the leading segments of the SBS market during future growth. The only available GLP-2 analog in the market for the treatment of SBS is Gattex/Revestive. The strong growth of this segment can be attributed to the increase in prescriptions for gattex therapy, the rise in the number of patients on gattex therapy, and the high cost of the drug. 

• Gattex/Revestive is commercially available in North America and selected countries in Europe, including the U.K., Germany, France, Italy, Spain, and the Nordics. 

• The high cost of parenteral nutrition increases the demand 

• Growth hormone approved for treatment of short bowel syndrome 

Challenges: 

• High cost of treatment to hamper the market 

• The cost of treatment of rare diseases is significantly high, which makes the treatment unaffordable for developing countries. Additionally, the lack of reimbursement in certain countries renders the treatment unreachable to various significant groups of people. 

• In May 2019, Gattex (teduglutide) received approval from the FDA for injection to pediatric patients 1 year of age and older with SBS. Gattex is quite expensive, with treatment costing over USD 295,000 a year 

• The cost of treatment for the lifetime renders the treatment unaffordable, as rare diseases are life-threatening and do not have a permanent cure, therefore leading to a decrease in the number of patients preferring to avail of the treatment 

• Lack of skilled professionals 

Competitive Landscape: 

Takeda Pharmaceutical Company Limited (Japan), VectivBio AG, 9 Meters Biopharma, Zealand Pharma (Denmark), Hikma Pharmaceuticals (U.K.), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), GSK Plc. (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Merck KGaA (Germany), Swedish Orphan Biovitrum (Switzerland), OxThera, Mylan (US), AstraZeneca (UK), and Others. 

Key Developments: 

Competitors in the global short bowel syndrome market are engaged in regulatory approvals, the development of new services, and acquisition & collaborative agreements with other companies. A few expansion strategies are adopted by players operating in the SBS market. 

Get more details on this report - Request Free Sample

Regional Analysis: 

North America is expected to dominate the overall short bowel syndrome market throughout the forecast period. This anticipated is mainly due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, the rise in the busy lifestyle that led to no time to focus on nutritious and healthy food with increased consumption of unhealthy products and junk food, resultant intestinal disorders (prevalence in the US is approximately 30 cases per million) are a major factor that drives the market growth in the region.

In addition, an increase in extended shelf life, marginal nutritional changes in food & beverage products such as milk, and a reduction in logistics and storage costs are the key factors owing to the growth in the segment during the forecast period. 

Europe also remains a favorable region after North America. It has approximately 1.4 cases per million. In recent times, there is increasing use of anti-diarrheal, histamine blockers, and proton pump inhibitors in SBS therapeutic platforms. Additionally, the growing aging population, lifestyle factors, and increasing awareness of healthcare are some of the key driving factors for the high price growth of the parenteral nutrition segment.                                      

Moreover, a few significant competitive players (Zealand Pharma, Sanofi, GSK Plc., Hikma Pharmaceuticals, and others) are focused on various R&D activities in the business space and are expected to stimulate the demand for SBS through 2027. 

Asia Pacific is anticipated to grow at the fastest rate during the forecast period due to the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in developing countries like India and Japan. Also, the research activities and investments in R&D in the region are estimated to fuel the growth of the SBS market in the Asia Pacific and impact a significant share of the global market. In addition, competitors in the Asia-Pacific SBS market are engaged in the acquisition of other companies. For instance,  

• In January 2019, Takeda Pharmaceutical Company Limited acquisition with Shire plc,(Japan). With this combination, Takeda has an attractive, expanded geographic footprint and leading position in Japan. Similarly, bringing its highly innovative medicines to employees across the world. 

The short Bowel Syndrome market in the MEA is gaining significant progress on account of various factors including government initiatives to encourage medical tourism, evolving health insurance policies, and growing propensity among the local population to consume digital health services. The SBS market is primarily increasing in five countries such as Saudi Arabia, Iran, Israel, Egypt, and UAE. Moreover, all together cover more than 85% of the Middle East healthcare market. 

Lack of awareness and healthcare facilities in Latin America will contribute to poor growth SBS market, in addition, a lack of approved treatment options may lead to the slow growth of the SBS market. However, from the initiates by many government bodies, pharmaceutical companies, health ministries, and NGOs conduct health programs and camps to educate the people and raise awareness to the market players distributing free samples and kits for educating the people and promoting their drugs is anticipated to propel the SBS Market during the forecast period 2022-2027.  

Pipeline: 

The short bowel syndrome pipeline landscape is evolving with increased insight into significant biological pathways and mechanisms underlying SBS treatment, leading to further targeting and pipeline therapies in various stages of clinical development, key companies are working to enhance the pipeline space and anticipated growth potential of the SBS pipeline platform. 

• In October 2022, Zealand Pharma received FDA approval for Orphan drug designation to Glepaglutide (long-acting GLP-2 analog) in the treatment of SBS, and is currently being studied in Phase 3 clinical trials. 

• In April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for SBS. 

• In June 2021, VectivBio Holding AG received FDA approval for Orphan drug designation to Apraglutide, a next-generation, long-acting GLP-2 analog in rare gastrointestinal (GI) diseases, and VectivBio AG plans to initiate a phase 2 trial evaluating Apraglutide for the treatment of aGVHD in 2022. 

• In May 2019, GATTEX (teduglutide) received U.S. FDA approval for injection to pediatric patients one year of age and older with SBS who need additional nutrition/fluids from intravenous. 

Segmentation: 

• The global short bowel syndrome market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Product 

• Glucagon-like Peptide-2 (GLP2) 

• Growth Hormone 

• Glutamine 

• Others 

• The global short bowel syndrome market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Distribution Channel 

• Hospital Pharmacies 

• Retail Pharmacies 

• Online Sales 

What is the Short Bowel Syndrome Market Report about? 

The short bowel syndrome market report discusses the commercial and clinical activity associated with applications. It provides insights on the total size of the potential opportunity, key segments driving growth, key challenges faced, and a thorough analysis of market competition by product, geography, indication, and forecasts through 2027. Detailed coverage of the approved short bowel syndrome, including regulatory approvals, pricing, reimbursement, and market penetration.

So, a new investor can potentially gain information about short bowel syndrome companies, their key products, their core strategy, key trends in the short bowel syndrome market, and more. The short bowel syndrome market report is essential for all stakeholders including research companies, manufacturing companies, distribution companies, government agencies, and others. 

• Capitalize on rapidly emerging trends 

• Optimize decision-making 

• Reduce company risk 

• Approach partners/investors for collaboration or funding 

• Implement an informed and advantageous business strategy in 2022 

• Detailed coverage of the approved short bowel syndrome products, including regulatory approvals, pricing, reimbursement, and market penetration 

• Profiles of leading & upcoming short bowel syndrome competitors composing the global marketplace